MarketLens

Log in
Stock AnalysisPro

Is D3 Bio's Elisrasib a Game-Changer in KRAS G12C NSCLC

1 months ago
SHARE THIS ON:

Is D3 Bio's Elisrasib a Game-Changer in KRAS G12C NSCLC

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

What Did D3 Bio Present at ASCO 2026 for Elisrasib

What Did D3 Bio Present at ASCO 2026 for Elisrasib

1 months ago
Is PetroChem Innovate's New Bio-Plastic a Game Changer for the Industry

Is PetroChem Innovate's New Bio-Plastic a Game Changer for the Industry

2 months ago
What Makes Elisrasib's ASCO 2026 Data So Significant

What Makes Elisrasib's ASCO 2026 Data So Significant

1 months ago
What is Latus Bio's "Gene Therapy 2.0" and Why Does it Matter

What is Latus Bio's "Gene Therapy 2.0" and Why Does it Matter

2 months ago

Category

TopFeaturedPro OnlyStock AnalysisInvestment IdeasETFsCryptoNew Release

You may also like

Stock News•3 weeks ago

Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC

Pfizer's phase III NSCLC trial for Sigvotatug Vedotin missed a key survival endpoint overall, though a large subgroup showed favorable survival trends versus docetaxel.
PFE
Stock News•1 months ago

D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC

D3 Bio reported first-line clinical data for its next-generation KRAS G12C inhibitor, elisrasib (D3S-001), at the ASCO 2026 conference. The study highlights landmark efficacy results for the drug in p...
Stock News•2 months ago

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

Silexion Therapeutics reported statistically significant increases in MHC-I expression following SIL204 treatment in preclinical KRAS-mutated pancreatic and lung cancer cells. These findings support p...
SIL
Stock News•2 months ago

Elicio Therapeutics: Hoping To Capitalize On Massive KRAS Hype, But Time Is Running Out

Elicio Therapeutics faces a critical 2026 as it approaches a pivotal KRAS peptide vaccine trial readout. While the data could serve as a significant catalyst for the company, ongoing concerns regardin...
ELTX

Breaking News

View All →
Earnings
Regional Banks
Earnings Surprise
Biotech & Pharma
Corporate Earnings
Debt/Share Issuance
Financials
Free Cash Flow (FCF)
M&A
Radiopharmaceuticals

Featured Articles

Kinder Morgan's Insider Sales: A Planned Exit, Not a Red Flag, for a Resilient Midstream Giant

Kinder Morgan's Insider Sales: A Planned Exit, Not a Red Flag, for a Resilient Midstream Giant

57 minutes ago
Cerus CEO's Recent Stock Sale: A Planned Liquidity Event Amidst a Strategic Transition

Cerus CEO's Recent Stock Sale: A Planned Liquidity Event Amidst a Strategic Transition

58 minutes ago
Snap's Executive Exodus: Why Insider Sales Signal Deeper Doubts Beyond Tax Obligations

Snap's Executive Exodus: Why Insider Sales Signal Deeper Doubts Beyond Tax Obligations

1 hour ago

Top Headlines

View More →
Stock News•38 minutes ago

Rosen Law Firm Encourages Alibaba Group Holding Limited Investors to Inquire About Securities Class Action Investigation - BABA

Stock News•1 hour ago

Jimothy keeps on giving: Amazon and others match winning bid for raccoon art, to benefit food bank

Stock News•1 hour ago

Chipotle Mexican Grill (CMG) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Stock News•1 hour ago

Microsoft (MSFT) Ascends While Market Falls: Some Facts to Note

Stock News•1 hour ago

Securities Fraud Investigation Into Alphabet Inc. (GOOG) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz